NXGLW
Price:
$0.48
Market Cap:
$26.24M
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It provides facemasks, undereye patches, blister shield foot care, hexagel, cracked heel repair patches, and fever patch. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was founded in 1997 and is based in Langhorne, Pennsylvania.[Read more]
Industry
Medical - Instruments & Supplies
IPO Date
Stock Exchange
NASDAQ
Ticker
NXGLW
According to NEXGEL, Inc.’s latest financial reports and current stock price. The company's current ROE is -69.99%. This represents a change of 288.41% compared to the average of -18.02% of the last 4 quarters.
The mean historical ROE of NEXGEL, Inc. over the last ten years is -621.01%. The current -69.99% ROE has changed -88.73% with respect to the historical average. Over the past ten years (40 quarters), NXGLW's ROE was at its highest in in the June 2019 quarter at 1.82%. The ROE was at its lowest in in the December 2020 quarter at -959.15%.
Average
-621.01%
Median
-188.08%
Minimum
-3214.08%
Maximum
-52.20%
Discovering the peaks and valleys of NEXGEL, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 535.13%
Maximum Annual ROE = -52.20%
Minimum Annual Increase = -98.38%
Minimum Annual ROE = -3214.08%
Year | ROE | Change |
---|---|---|
2023 | -67.21% | -16.45% |
2022 | -80.45% | 54.13% |
2021 | -52.20% | -98.38% |
2020 | -3214.08% | 535.13% |
2019 | -506.05% | -24.68% |
2018 | -671.89% | 340.64% |
2017 | -152.48% | -31.83% |
The current ROE of NEXGEL, Inc. (NXGLW) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-66.62%
5-year avg
-784.00%
10-year avg
-621.01%
NEXGEL, Inc.’s ROE is greater than NEXGEL, Inc. (-69.99%), less than NLS Pharmaceutics AG (22.54%), less than NeuroSense Therapeutics Ltd. (313.10%), greater than Pasithea Therapeutics Corp. (-74.63%), less than Cingulate Inc. (11.47%),
Company | ROE | Market cap |
---|---|---|
-69.99% | $26.24M | |
22.54% | $7.33M | |
313.10% | $25.05M | |
-74.63% | $3.78M | |
11.47% | $11.86M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NEXGEL, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NEXGEL, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is NEXGEL, Inc.'s ROE?
How is the ROE calculated for NEXGEL, Inc. (NXGLW)?
What is the highest ROE for NEXGEL, Inc. (NXGLW)?
What is the 3-year average ROE for NEXGEL, Inc. (NXGLW)?
What is the 5-year average ROE for NEXGEL, Inc. (NXGLW)?
How does the current ROE for NEXGEL, Inc. (NXGLW) compare to its historical average?